Shaheenah Dawood, Consultant Medical Oncologist at Mediclinic Middle East, shared on LinkedIn:
“This study provides evidence for incorporating TP53-based molecular risk stratification into first-line clinical decision-making because the efficacy of intensified combination therapy justifies the added treatment-related burden in this high-risk population.”
Other articles featuring Shaheenah Dawood on OncoDaily.